Biliary Tract Cancer Clinical Trial
— TOURMALINEOfficial title:
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE)
A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.
Status | Recruiting |
Enrollment | 140 |
Est. completion date | March 17, 2026 |
Est. primary completion date | September 17, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 130 Years |
Eligibility | Inclusion Criteria: - Histologically confirmed, unresectable advanced or metastatic biliary tract carcinoma (BTC) including cholangiocarcinoma (intrahepatic or extrahepatic), gallbladder carcinoma, and ampulla of Vater (AoV) carcinoma - Participants with unresectable or metastatic BTC - A World Health Organisation Eastern Cooperative Oncology Group Performance Status (WHO/ECOG PS) of 0 to 2 - At least one lesion that qualifies as a Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) target lesion at baseline - Adequate organ and bone marrow function - Body weight of > 30 kg - Negative pregnancy test (serum) for women of childbearing potential - Female participants must be one year post-menopausal (amenorrhoeic for 12 months without an alternative medical cause) - Male and female participants and their partners must be surgically sterile or on their chosen method of birth control as per the protocol. Exclusion Criteria: - Any evidence of diseases such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diseases, active infection, active interstitial lung disease/pneumonitis, serious chronic gastrointestinal conditions associated with diarrhoea, psychiatric illness/social situations, history of uncontrolled or symptomatic cardiac disease, and history of allogenic organ transplant - Active or prior documented autoimmune or inflammatory disorders - History of another primary malignancy, except for malignancy treated with curative intent and with no known active disease = 5 years before the first dose of study intervention - History of leptomeningeal carcinomatosis - History of active primary immunodeficiency - Known to have tested positive for human immunodeficiency virus [HIV] (positive HIV 1/2 antibodies) or active tuberculosis infection - Participants co-infected with Hepatitis B virus (HBV) and Hepatitis C virus (HCV) or co-infected with HBV and Hepatitis D virus (HDV) - Persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAE] Grade > 1) caused by previous anticancer therapy - Central nervous system metastases requiring treatment or history of spinal cord compression - Known allergy or hypersensitivity to any of the study intervention or any of the study intervention excipients. - Any concurrent chemotherapy, other than the one allowed in the study, investigational medicinal product (IMP), biologic, or hormonal therapy for cancer treatment - Palliative radiotherapy with a limited field of radiation within 2 weeks of the first dose of study intervention, or radiotherapy with a wide field of radiation or radiotherapy affecting more than 30% of the bone marrow within 4 weeks before the first dose of study intervention - Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention - Major surgical procedure within 28 days prior to the first dose of IMP - Prior exposure to immune-mediated therapy excluding therapeutic anticancer vaccines - Receipt of the last dose of anticancer therapy within 28 days prior to the first dose of IMP |
Country | Name | City | State |
---|---|---|---|
France | Research Site | Clichy | |
France | Research Site | Dijon | |
France | Research Site | Lyon Cedex 03 | |
France | Research Site | Montpellier Cedex 5 | |
France | Research Site | Pessac | |
France | Research Site | Rennes | |
France | Research Site | Villejuif | |
Germany | Research Site | Chemnitz | |
Germany | Research Site | Freudenstadt | |
Germany | Research Site | Hannover | |
Germany | Research Site | Muenchen | |
Italy | Research Site | Castelfranco Veneto | |
Italy | Research Site | Foggia | |
Italy | Research Site | Palermo | |
Italy | Research Site | Pisa | |
Italy | Research Site | Rozzano | |
Japan | Research Site | Chuo-ku | |
Japan | Research Site | Kanazawa-shi | |
Japan | Research Site | Kashiwa | |
Japan | Research Site | Kyoto | |
Japan | Research Site | Osaka | |
Japan | Research Site | Sendai | |
Japan | Research Site | Ube | |
Japan | Research Site | Wakayama | |
Japan | Research Site | Yokohama | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Singapore | Research Site | Singapore | |
Singapore | Research Site | Singapore | |
Singapore | Research Site | Singapore | |
Spain | Research Site | Barcelona | |
Spain | Research Site | Barcelona | |
Spain | Research Site | Madrid | |
Spain | Research Site | Madrid | |
Spain | Research Site | Madrid | |
Spain | Research Site | Madrid | |
Spain | Research Site | Pamplona | |
Spain | Research Site | Sevilla | |
United States | Research Site | Mobile | Alabama |
United States | Research Site | New York | New York |
United States | Research Site | Oklahoma City | Oklahoma |
United States | Research Site | Orange | California |
United States | Research Site | Portland | Oregon |
United States | Research Site | Washington | District of Columbia |
United States | Research Site | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United States, France, Germany, Italy, Japan, Korea, Republic of, Singapore, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with Grade 3 or 4 possibly related adverse event (PRAE) | PRAE is defined as an AE which has been assessed by the investigator to be possibly related to IMP. | Within 6 months after the initiation of Investigational Medicinal Product (IMP) | |
Secondary | Overall Survival (OS) | OS is defined as the time from the date of the first dose of IMP until death due to any cause. | From the date of the first dose of IMP until death due to any cause [approx. upto 33 months] | |
Secondary | Objective Response Rate (ORR) | ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by the investigator at local site per RECIST 1.1. | From the date of first dose of IMP until progression, or the last evaluable assessment in the absence of progression [assessed up to 33 months] | |
Secondary | Progression-Free Survival (PFS) | PFS is defined as the time from the first dose of IMP until the date of disease progression (PD) or death due to any cause. | From the date of the first dose of IMP until until the date of objective PD or death [approx. up to 33 months] | |
Secondary | Disease Control Rate (DCR) | DCR is defined as the % of participants who have a best objective response of complete response or partial response (by week 24 or 32), or who have stable disease for 24 or 32 weeks. | Week 24 and Week 32 | |
Secondary | Duration of Response (DOR) | DOR is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression. | From the date of first documented response until the first date of documented progression or death in the absence of disease progression [approx. up to 33 months] | |
Secondary | Duration of Treatment (DOT) | DOT is defined as time on study intervention. | From date of start of IMP, until 27 days after last dose of IMP or date of death [approx. up to 33 months] | |
Secondary | Number of participants with AEs, including PRAEs, adverse events of special interest (AESIs), immune-mediated adverse events (imAEs) and serious adverse events (SAEs) | To assess the safety and tolerability profile of durvalumab combined with background gemcitabine-based chemotherapy | From the date of first dose of IMP until long-term follow-up i.e. until 90 days following discontinuation of the last dose of IMP [approx. up to 33 months] | |
Secondary | Number of participants with IRRs and hypersensitivity/anaphylactic reactions | To assess the safety and tolerability profile of durvalumab combined with background gemcitabine-based chemotherapy | From the date of first dose of IMP until 90 days following discontinuation of the last dose of IMP [approx. up to 33 months] | |
Secondary | European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire (EORTC QLQ C-30) | To assess disease and treatment related symptoms and HRQoL. EORTC QLQ-C30 consists of 30 items and measures symptoms, functioning, and global health status/QoL for all cancer types. Questions are grouped into 5 multi-item functional scales (physical, role, emotional, cognitive, and social), 3 multi-item symptom scales (fatigue, pain, and nausea/vomiting), a 2-item global QoL scale, 5 single items assessing additional symptoms commonly reported by cancer participants (dyspnoea, loss of appetite, insomnia, constipation, and diarrhoea), and one item on the financial impact of the disease. The EORTC QLQ-C30 is a valid and reliable PRO instrument in this participant population | From date of first dose of IMP, until the date of the first clinically meaningful deterioration [approx. up to 33 months] | |
Secondary | EORTC QLQ-BIL21 Score | To assess disease- and treatment related symptoms and HRQoL. The EORTC QLQ-BIL21 is a disease-specific (cholangiocarcinoma and cancer of the gallbladder) questionnaire. It consists of 21 items including one question each for side effects, equipment issues, and weight loss, as well as 5 scales (eating symptoms, jaundice symptoms, tiredness, pain, and anxiety). A higher score indicates greater difficulties. The EORTC QLQ-BIL21 is a valid and reliable PRO instrument in this participant population. | From date of first dose of IMP, until the date of the first clinically meaningful deterioration [approx. up to 33 months] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Withdrawn |
NCT03110510 -
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00380588 -
Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
Terminated |
NCT00090025 -
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors
|
Phase 3 | |
Terminated |
NCT04066491 -
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
|
Phase 2/Phase 3 | |
Recruiting |
NCT05998447 -
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
|
Phase 2 | |
Recruiting |
NCT03718897 -
Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing
|
||
Recruiting |
NCT05056116 -
A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer
|
N/A | |
Recruiting |
NCT04692051 -
A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
|
Phase 2 | |
Terminated |
NCT04057365 -
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
|
Phase 2 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT02829918 -
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
|
Phase 2 | |
Recruiting |
NCT04584996 -
CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers
|
||
Completed |
NCT02579616 -
Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy
|
Phase 2 | |
Recruiting |
NCT05052099 -
Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT01494363 -
Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
|
Phase 2 | |
Completed |
NCT00753675 -
Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
|
Phase 2 | |
Terminated |
NCT00630890 -
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
|
Phase 1 | |
Recruiting |
NCT04445532 -
Hepatobiliary Tumors Tissue Samples Acquisition
|